ACCURADX

Welcome to the Brand page for “ACCURADX”, which is offered here for The mark consists of the wording accuradx with a dna symbol partially circling the letters dx.;downloadable computer software that is focusing on bioinformatics analyses of ngs data for research use only and/or medical?diagnostic purposes via laboratory-developed tests (ldts) and fda-approved in vitro diagnostics (ivds);genetics, genomics and epigenomics-related reagents for medical diagnostic purposes via laboratory-developed tests (ldts) and fda-approved in vitro diagnostics (ivds);genetics, genomics and epigenomics-related reagents for research use, including for nucleic acid and protein sample preparation for next-generation sequencing (ngs);research, analytical and consulting services that focus on next-generation sequencing (ngs) and sample preparation therefor,?performance for ngs, and services regarding dna and rna mapping technologies including kas-seq, keth-seq, cap-c, and?services assisting researchers using of ngs technologies; research, analytical and consulting services for medical diagnostic?purposes via laboratory-developed tests (ldts) and fda-approved in vitro diagnostics (ivds); software as a service (saas) services analytic platform focusing on bioinformatics analyses of ngs data for research use only and/or and future medical diagnostic purposes via laboratory-developed tests (ldts) and fda-?approved in vitro diagnostics (ivds);.

Its status is currently believed to be active. Its class is unavailable. “ACCURADX” is believed to be currently owned by “AccuraDX Inc.”


Owner:
ACCURADX INC.
Owner Details
Description:
The mark consists of the wording ACCURADX with a DNA symbol partially circling the letters DX.;Downloadable computer software that is focusing on bioinformatics analyses of NGS data for research use only and/or medical?diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);genetics, genomics and epigenomics-related reagents for medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);genetics, genomics and epigenomics-related reagents for research use, including for nucleic acid and protein sample preparation for next-generation sequencing (NGS);Research, analytical and consulting services that focus on next-generation sequencing (NGS) and sample preparation therefor,?performance for NGS, and services regarding DNA and RNA mapping technologies including KAS-seq, Keth-seq, CAP-C, and?services assisting researchers using of NGS technologies; research, analytical and consulting services for medical diagnostic?purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs); software as a service (SAAS) services analytic platform focusing on bioinformatics analyses of NGS data for research use only and/or and future medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-?approved in vitro diagnostics (IVDs);
Categories: